Erratum to: Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia

Cardiovasc Drugs Ther Erratum to: Eff icacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia Robert S. Rosenson 0 1 2 3 4 5 6 Terry A. Jacobson 0 1 2 3 4 5 6 David Preiss 0 1 2 3 4 5 6 Stephen C. Djedjos 0 1 2 3 4 5 6 Ricardo Dent 0 1 2 3 4 5 6 Ian Bridges 0 1 2 3 4 5 6 Michael Miller 0 1 2 3 4 5 6 0 Emory University , 201 Dowman Drive, Atlanta, GA 30322 , USA 1 Mount Sinai Heart, Cardiometabolics Unit, Icahn School of Medicine at Mount Sinai , 1425 Madison Ave, MC1 Level, New York, NY 10029 , USA 2 University of Maryland School of Medicine , 655 W Baltimore St, Baltimore, MD 21201 , USA 3 Amgen Ltd , 240 Cambridge Science Park, Milton, Cambridge CB4 0WD , UK 4 Amgen (Europe) GmbH , Dammstrasse 23, 6300 Zug , Switzerland 5 Amgen Inc., One Amgen Center Dr , Thousand Oaks, CA 91320 , USA 6 Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford University , Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF , UK mistake. In the Results of the Abstract section, where it says "…compared to −6 % vs. placebo and −39 % vs. ezetimibe…" it should read "…compared to −65 % vs; placebo and −39 % (...truncated)